Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men

Vaccine

Volumn 24, Issue 42-43, 2006, Pages 6526-6533

  Imoukhuede, E B ^a,c   Berthoud, T ^b   Milligan, P ^a   Bojang, K ^a,c   Ismaili, J ^a   Keating, S ^b   Nwakanma, D ^a   Keita, S ^a   Njie, F ^a   Sowe, M ^a   Todryk, S ^b   Laidlaw, S M ^d   Skinner, M A ^d   Lang, T ^b   Gilbert, S ^b   Greenwood, B M ^c   Hill, A V S ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Immunogenicity; Malaria vaccines; Prime boost

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; MALARIA VACCINE; VIRUS VECTOR;

ADULT; ARM INJURY; ARTICLE; BIOCHEMISTRY; BLISTER; CELLULAR IMMUNITY; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; EXPRESSION VECTOR; FOWLPOX VIRUS; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE DISCOLORATION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MALAISE; MALARIA; MALE; NAUSEA; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VOMITING;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY SPECIFICITY; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAMBIA; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERFERON-GAMMA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PHENOTYPE; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES;

EID: 33749449876     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.022     Document Type: Article

References (29)

1. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson J.K., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4 (1998) 397-402
2. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Tine J.A., and Hoffman S.L. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 95 (1998) 7648-7653
3. Dunachie S.J., and Hill A.V.S. Prime-boost strategies for malaria vaccine development. J Exp Biol 206 (2003) 3771-3779
4. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9 (2003) 729-735
5. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomized, controlled, double-blind efficacy trial of DNA/MVA ME-TRAP prime-boost immunization against malaria infection in Gambian adults. PloS Med 1 2 (2004) e33
6. Vuola J.M., Keating S., Webster D.P., Berthoud T., Dunachie S., Gilbert S.C., et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174 (2005) 449-455
7. Moorthy V.S., Imoukhuede E.B., Keating S., Pinder M., Webster D., Skinner M.A., et al. Phase 1 evaluation of three highly immunogenic prime-boost regimens for malaria vaccination in Gambian adults including a 12-month re-boosting vaccination. J Infect Dis 189 (2004) 2213-2219
8. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T-cell mediated protection against malaria in human challenges by using the recombinant pox virus FP9 and modified vaccinia virus Ankara. Proct Natl Acad Sci USA 102 (2005) 4836-4841
9. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS, S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomized trial. Lancet 358 (2001) 1927-1934
10. Kester K.E., Mckinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183 (2001) 640-647
11. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., et al. Efficacy of the RTS, S/ASO2A vaccine against Plasmodium falciparum and disease in young African children: randomized controlled trial. Lancet 364 (2004) 1411-1420
12. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Aide P., et al. Duration of protection with RTS, S/ASO2 malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 (2005) 2012-2018
13. Moorthy V.S., Pinder M., Reece W.H., Watkins K., Atabani S., Hannan C., et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara in African adults. J Infect Dis 188 (2003) 1239-1244
14. Moorthy V.S., Mcconkey S., Roberts M., Gothard P., Arulanantham N., Degano P., et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 21 (2003) 1995-2002
15. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V.S., and McMichael A.J. Rapid effector function in CD8+ memory T cells. J Exp Med 186 (1997) 859
16. Good M.F., Maloy W.L., Lunde M.N., Margalit H., Cornette J.L., Smith G.L., et al. Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 235 (1987) 1059-1062
17. Good M.F., Pombo D., Quakyi I.A., Riley E.M., Houghten R.A., Menon A., et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 85 (1988) 1199-1203
18. Lalvani A., Hurt N., Aidoo M., Kibatala P., Tanner M., and Hill A.V. Cytotoxic T lymphocytes to P.falciparum epitopes in an area of intense and perennial transmission in Tanzania. Eur J Immunol 26 (1996) 773-779
19. Plebanski M., Aidoo M., Whittle H.C., and Hill A.V. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol 158 (1997) 2849-2855
20. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and diseases. Nat Med 10 (2004) 406-410
21. Lalvani A., Moris P., Voss G., Pathan A.A., Kester K.E., Brookes R., et al. Potent induction of focused Th1 -type cellular and humoral immune responses by RTS, S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J Infect Dis 180 (1999) 1656-1664
22. Lanar D.E., Tine J.A., de Taisne C., Seguin M.C., Cox W.I., Winslow J.P., et al. Attenuated vaccina virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun 64 (1996) 1666-1671
23. Pinder M., Reece W.H., Plebaski M., Akinwumi P., Flanagan K.L., Lee E.A., et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS, S/ASO2, in semi-immune adults in The Gambia. Clin Exp Immunol 135 (2004) 286-293
24. Gordon D.M., McGovern T.W., Krzych U., Cohen J.C., Schneider I., LaChance R., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171 (1995) 1576-1585
25. Walther M., Dunachie S., Keating S., Vuola J.M., Berthoud T., Schmidt A., et al. Safety and immunogenicity of a pre-erythrocytic malaria candidate vaccine, ICC-1132. Vaccine 23 (2005) 854-864
26. Lopez J.A., Weilenman C., Audran R., Roggero M.A., Bonelo A., Tiercy J.M., et al. A synthetic malaria vaccine elicits a potent CD8+ and CD4+ T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol 31 (2001) 1989-1998
27. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., et al. Induction of CD4+ cell-dependent CD8+ type1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 98 (2001) 10817-10822
28. Dunachie S.J., Walther M., Vuola J.M., Webster D.P., Keating S.M., Berthoud T., et al. A clinical trial of prime-boost immunization with the candidate malaria vaccines RTS, S/ASO2 and MVA-CS. Vaccine 24 (2006) 2850-2859
29. Walther M., Thompson F., Dunachie S., Keating S., Todryk S., Berthoud T., et al. Safety, immunogenicity and efficacy of prime-boost immunization with recombinant poxvirus FP9 and Modified Virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 74 (2006) 2706-2716